Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clin Cancer Res. 2015;21(23):5277-85.

Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, et al. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015;33(11):495.e15-22.

Piva R, Deaglio S, Famà R, Buonincontri R, Scarfò I, Bruscaggin A, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia. 2015;29(2):503-7.

Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, M Y Wang V, et al. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov. 2015;5(6):636-51.

O-Sullivan IS, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, et al. Erratum: FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 2015;6:7861.

The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015;163(4):1011-25.

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(2):113-23.

2014

Ferrante M, Khan A, Fan C, Jelloul FZ. Schwannoma of the cervical esophagus. Rare Tumors. 2014;6(2):5361.

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, et al. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174(8):1301-7.

Vogel MJ, Xie L, Guan H, Tooze RM, Maier T, Kostezka U, et al. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood. 2014;124(20):3118-29.